Peptide Therapy Insights
Evidence-based guides, regulatory updates, and expert perspectives on peptide therapy. Stay informed with the latest research and clinical insights.
FDA's Crackdown on Compounded GLP-1 Drugs: What Patients Need to Know in 2026
The FDA removed semaglutide and tirzepatide from its drug shortage list in early 2025, ending the compounding exemption that had allowed hundreds of pharmacies to produce GLP-1 copies at lower cost. Here's what that means for your access, your wallet, and your options right now.
More in Regulatory
RegulatoryFDA Peptide Regulations Explained: What's Actually Regulated in 2026
The FDA's regulatory framework for peptides is more complex — and more consequential — than most patients realize. Here's what's actually regulated, what isn't, and what you need to know before starting any peptide therapy in 2026.
RegulatoryTirzepatide Legal Status in 2026: Approved as Mounjaro & Zepbound, Compounding Now Banned
Explore the current legal status of tirzepatide, including FDA approval, compounding legality, and enforcement actions. Understand what this means for patients and what alternatives are available.
RegulatoryIs CJC-1295 / Ipamorelin Legal? FDA Status and Regulations Explained (2026)
Explore the legal status of CJC-1295 / Ipamorelin, including FDA approval, compounding regulations, and what this means for patients seeking peptide therapy.
RegulatoryIs GHK-Cu Legal? FDA Status and Regulations Explained (2026)
Explore the FDA status, compounding legality, and enforcement actions related to GHK-Cu peptide as of 2026. Understand what 'research use only' entails and practical implications for patients.
RegulatoryIs Sermorelin Legal? FDA Status and Regulations Explained (2026)
Explore the legal status of Sermorelin, including its FDA approval, compounding legality, and implications for patients.
RegulatoryIs PT-141 Legal? FDA Status and Regulations Explained (2026)
Explore the legal status of PT-141, its FDA approval, compounding legality, and what patients need to know about its availability in Canada.
RegulatoryIs BPC-157, TB-500 (Blend) Legal? FDA Status and Regulations Explained (2026)
Explore the legal status of BPC-157, TB-500 (Blend) in 2026, including FDA regulations, compounding legality, and what patients need to know.
RegulatoryIs BPC-157, TB-500, KPV, GHK-Cu 80mg (Klow Blend) Legal? FDA Status and Regulations Explained (2026)
Explore the legal status of BPC-157, TB-500, KPV, and GHK-Cu 80mg (Klow Blend), including FDA regulations, compounding legality, and enforcement actions as of 2026.
Stay Up to Date
New articles on peptide therapy, FDA regulations, and clinic reviews are published regularly. Bookmark this page or check back often.